| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Plantamajoside targets multiple pathways. It inhibits cAMP phosphodiesterase and 5-lipoxygenase. It inactivates NF-κB, PI3K/Akt, and MAPK pathways. It induces apoptosis and improves autophagy. Its anti-tumor effects are mediated through the inhibition of matrix metalloproteinase-9 and -2.
|
|---|---|
| ln Vitro |
In vitro, plantamajoside has antibacterial activity against E. coli, S. aureus, and several plant pathogenic bacteria. It has inhibition activity against cAMP phosphodiesterase and 5-lipoxygenase. It demonstrates antioxidant activity. It inhibits the activity of matrix metalloproteinase-9 and -2.
|
| ln Vivo |
In vivo, plantamajoside has protective effects in a mouse model of LPS-induced acute lung injury. It ameliorates LPS-induced acute lung injury via suppressing NF-κB and MAPK activation. It has protective activities against cadmium-induced renal injury. It also has anti-tumor effects.
|
| Enzyme Assay |
In vitro enzyme assays for plantamajoside measure its inhibition of cAMP phosphodiesterase and 5-lipoxygenase. The compound is incubated with the enzyme and a substrate, and the reaction is monitored spectrophotometrically or by HPLC. Its antioxidant activity is assessed using standard cell-free assays such as DPPH and ABTS.
|
| Cell Assay |
In vitro cell-based assays for plantamajoside involve treating cancer cells (e.g., breast cancer cells) with the compound and measuring cell viability, migration, and invasion. Its effects on MMP-9 and MMP-2 activity are assessed by gelatin zymography. Its anti-inflammatory effects are studied in immune cells.
|
| Animal Protocol |
In vivo animal experiments for plantamajoside have been conducted in a mouse model of LPS-induced acute lung injury. Mice are treated with the compound, and lung inflammation is assessed by measuring inflammatory markers and histopathology. Its anti-tumor effects have been studied in mouse models of breast cancer.
|
| ADME/Pharmacokinetics |
Plantamajoside has a molecular weight of 640.59 and a molecular formula of C29H36O16. It is a white powder. It is soluble in methanol and water. It has a density of 1.66 g/cm3. It is typically stored under recommended conditions for natural products.
|
| Toxicity/Toxicokinetics |
Plantamajoside is for research use only and is not intended for human use. Its safety profile is being evaluated in preclinical studies. As a natural product, it is generally considered to have a favorable safety profile. Standard safety precautions should be taken when handling.
|
| References |
|
| Additional Infomation |
Plantamajoside is a hydroxycinnamic acid. It has been reported that plantamajoside is found in rehmannia, plantain, and other organisms with relevant data.
Plantamajoside is a phenylpropanoid glycoside from Plantago asiatica L.. It has antibacterial, antioxidant, anti-tumor, anti-inflammatory, and anti-skin photoaging effects. It inhibits breast cancer growth and metastasis. It has protective effects against acute lung injury and cadmium-induced renal injury. It is a bioactive caffeic acid derivative. |
| Molecular Formula |
C29H36O16
|
|---|---|
| Molecular Weight |
640.5866
|
| Exact Mass |
640.2
|
| CAS # |
104777-68-6
|
| PubChem CID |
5281788
|
| Appearance |
White to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
953.0±65.0 °C at 760 mmHg
|
| Flash Point |
308.5±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.705
|
| LogP |
-0.76
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
953
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O
|
| InChi Key |
KFEFLPDKISUVNR-QJEHNBJNSA-N
|
| InChi Code |
InChI=1S/C29H36O16/c30-11-19-22(37)23(38)24(39)29(42-19)45-27-25(40)28(41-8-7-14-2-5-16(33)18(35)10-14)43-20(12-31)26(27)44-21(36)6-3-13-1-4-15(32)17(34)9-13/h1-6,9-10,19-20,22-35,37-40H,7-8,11-12H2/b6-3+/t19-,20-,22-,23+,24-,25-,26-,27-,28-,29+/m1/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~156.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (1.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5611 mL | 7.8053 mL | 15.6106 mL | |
| 5 mM | 0.3122 mL | 1.5611 mL | 3.1221 mL | |
| 10 mM | 0.1561 mL | 0.7805 mL | 1.5611 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
